Reprogrammed T cells can eliminate senescent cells, new research shows

Single treatment CAR T cell therapy reduces age-related decline in mice and can protect against diabetes and obesity.
Researchers have discovered that T cells, a type of white blood cells, can be reprogrammed to seek out and destroy senescent cells.

Longevity.Technology:…Read More

The gut microbiome: A key to unlocking healthy aging
Gut health has huge implications for healthspan and longevity, and could hold the key to improving cognition, immunity and healthy aging.
You are not alone… in fact you have more than 100 trillion companions residing in your gut forming the microbiome. The intricate relationship between the h…Read More

Loyal launches pivotal dog lifespan extension trial

First dog dosed in study designed to demonstrate lifespan and healthspan extension in 1,000 senior dogs.
Longevity biotech company Loyal has initiated a clinical trial in the US for a drug designed to extend the healthy lifespan of senior dogs. The pivotal STAY study, involving over 1,000…Read More

Catalyzing a change in how we treat Alzheimer’s

Covalent Bioscience’s Stephanie Planque explains why longevity therapies should be converting to catalytic antibodies.
Covalent Bioscience was formed by Richard Massey, Sudhir Paul and Stephanie Planque to leverage catalytic antibody tech for unmet medical needs. Catalytic antibodies (so…Read More

Fractyl raises $110m IPO, nominates GLP-1 gene therapy candidate

Obesity drug developer plots path to human trials following NASDAQ debut in challenging IPO market.
Metabolic therapeutics company Fractyl Health raised $110 million in its initial public offering last week. The company, which floated on the NASDAQ under the symbol GUTS, has…Read More

New research supports therapeutic potential of senolytics in DME
Publication in Nature Medicine details long-lasting, disease-modifying intervention in vision loss from diabetic macular edema.
UNITY Biotechnology, a company working on therapeutics to slow, halt or reverse diseases of aging, today announced new research published in the…Read More

Anima claims ‘promising’ preclinical data for IPF drug candidate
Drug shows potential for IPF treatment by effectively disrupting the transformation of fibroblasts into fully differentiated myofibroblasts.
AI drug discovery company Anima Biotech has revealed encouraging preclinical results for its drug candidate addressing Idiopathic Pul…Read More

‘VCs should run experiments to derisk longevity biotech investments’
Ichor founder speaks out on some of the key challenges facing longevity drug developers and investors.
Longevity focused contract research organization Ichor Life Sciences recently revealed the expansion of its clinical services division, Ichor Clinical, to Australia, Eur…Read More

Neurona lands $120m to advance regenerative cell therapy pipeline
Company’s cell therapy candidates target long-term repair of dysfunctional neural networks associated with conditions including Alzheimer’s.
San Francisco-based biotech company Neurona Therapeutics has raised $120 million in a funding round to advance regenerative cell therapy can…Read More

Sudo Bio lands additional $30m for TYK2 inhibitors with potential in Alzheimer’s
Dementia Discovery Fund joins new investors, citing Sudo’s potential in multiple neuroinflammatory diseases, including Alzheimer’s.
US biopharma Sudo Biosciences has raised an additional $30 million in the second round of its Series B financing, bringing the total…Read More